跳至主要内容
临床试验/CTRI/2020/05/025340
CTRI/2020/05/025340已完成1 期

Clinical trial to evaluate the safety and efficacy of ShatPlus an Ayurvedic Proprietary Medicine as an intervention in adult patients with SARS-CoV-2 infection.

BVG Life Sciences Ltd BVG Group0 个研究点目标入组 60 人开始时间: 待定最近更新:

试验速览

阶段
1 期
状态
已完成
发起方
入组人数
60

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • SARS-CoV-2 positive nasopharyngeal swab
  • Mild to Moderately severe disease (NEWS score <= 8)
  • Signed informed consent must be obtained and documented according to AYUSH GCP, and national/local regulations

排除标准

  • Requiring ICU admission at screening
  • History of MI, Epileptic episodes
  • Any other comorbidity which is at critical stage at screening
  • Any other condition by which subject proves unfit from investigator perspective

研究者

发起方
BVG Life Sciences Ltd BVG Group

相似试验

Clinical trial of ShatPlus in SARS-CoV-2 Infection. | 临床试验